Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 17Glioma 16Breast Neoplasms 14Prostatic Neoplasms 13Neoplasms 13Brain Neoplasms 11Pancreatic Neoplasms 10Colorectal Neoplasms 10Neoplasm Metastasis 9Multiple Myeloma 9Melanoma 8Lymphoma, B-Cell 8Lymphoma 8Recurrence 7Sarcoma 6Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Skin Neoplasms 4Lung Neoplasms 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Solid Tumor 3Pituitary Neoplasms 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3

Interventions

sacituzumab govitecan 1pembrolizumab 1erdafitinib 1enfortumab vedotin 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Muscle Invasive Bladder Urothelial Carcinoma × 90 days × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡